RE:Approaching my Short Term TargetSome highlights on status: The market cap on the company is only $30 Million. Over $10 Million in annual sales. Q3 2017 (last quarter reported), sales were up 23% and that trend should accelerate further now that bioreactor is online. Current profit/loss is about breakeven - excluding one time items - and should be profitable soon given savings from Bioreactor. Assets $26 Million, Liabilities of $10 Million as at Q3 2017. Just the virology product business alone is worth more than the current share price, let alone potential from Kinlytic Urokinase , and Lumisort.